← Back to Search

Monoclonal Antibodies

PRO 140 SC 350 mg weekly injection (Group A) for HIV/AIDS

Phase 2 & 3
Waitlist Available
Research Sponsored by CytoDyn, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if a single drug, PRO 140, can keep HIV under control in patients who are stable on their current multi-drug treatment. The drug works by blocking the virus from entering cells. The goal is to see if patients can maintain their health with this simpler treatment.

Eligible Conditions
  • HIV/AIDS

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: PRO 140 SC 700 mg weekly injections (Group C)Experimental Treatment1 Intervention
PRO 140 700 mg (175 mg/mL) SC injections per week
Group II: PRO 140 SC 525 mg weekly injections (Group B)Experimental Treatment1 Intervention
PRO 140 525 mg (175 mg/mL) SC injections per week
Group III: PRO 140 SC 350 mg weekly injection (Group A)Experimental Treatment1 Intervention
PRO 140 350 mg (175 mg/mL) SC injections per week

Find a Location

Who is running the clinical trial?

CytoDyn, Inc.Lead Sponsor
23 Previous Clinical Trials
2,002 Total Patients Enrolled
~60 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top